Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS ...
Astellas Pharma Inc. and Vir Biotechnology Inc. have entered into a global strategic collaboration to advance VIR-5500.
Astellas and Vir Biotechnology collaborate to advance PSMA-targeting PRO-XTEN dual-masked T-cell engager VIR-5500 to treat prostate cancer: Tokyo Wednesday, February 25, 2026, 09: ...
Oncology Media Relations oncology_media_relations@its.jnj.com   Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...